Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials

Table 3 The subgroup analysis for PFS in patients with HCC

Subgroup		Number of studies	Pooled PFS		Heterogeneity
Subgroup		Number of studies	HR[95% CI]	p	I²	p
Region	Asia	4	0.54[0.48, 0.62]	< 0.00001	0%	0.85
Region	Non-Asia	3	0.70[0.57, 0.86]	0.0006	0%	0.74
AFP Lever	AFP < 400 ng/ml	3	0.53[0.45, 0.63]	< 0.00001	60%	0.08
AFP Lever	AFP ≥ 400 ng/ml	3	0.61[0.50, 0.75]	< 0.00001	83%	0.003
MVI or EHS	presence	4	0.56[048, 0.66]	< 0.00001	0%	0.93
MVI or EHS	absence	4	0.62[0.50, 0.75]	< 0.00001	41%	0.17
BCLC Stage	BCLC B	3	0.53[0.43, 0.67]	< 0.00001	34%	0.22
BCLC Stage	BCLC C	3	0.59[0.49, 0.70]	< 0.00001	0%	0.80
Etiology	Hepatitis B	4	0.53[0.47, 0.59]	< 0.00001	0%	0.79
	Hepatitis C	3	0.65[0.45, 0.92]	0.02	0%	0.93
	Non-viral	3	0.77[0.59, 1.00]	0.05	0%	0.57

ISSN: 1471-2407